Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Dec 1;3(12):e2028634.
doi: 10.1001/jamanetworkopen.2020.28634.

Assessment of Plasma Amyloid-β42/40 and Cognitive Decline Among Community-Dwelling Older Adults

Kelly Virecoulon Giudici  1 , Philipe de Souto Barreto  1   2 , Sophie Guyonnet  1   2 , Yan Li  3   4 , Randall John Bateman  3 , Bruno Vellas  1   2 ; MAPT/DSA Group
Affiliations
Randomized Controlled Trial

Assessment of Plasma Amyloid-β42/40 and Cognitive Decline Among Community-Dwelling Older Adults

Kelly Virecoulon Giudici et al. JAMA Netw Open. .

Abstract

Importance: Plasma measurement of amyloid-β (Aβ) peptides has been associated with cognitive function, but evidence of its ability to identify cognitive decline is still scarce.

Objective: To investigate the associations between plasma Aβ42/40 and cognitive decline over time among community-dwelling older adults with subjective memory concerns.

Design, setting, and participants: This multicenter cohort study used data from volunteers in the 5-year study Multidomain Alzheimer Preventive Trial (MAPT). Participants were aged 70 years or older and observed for a median (interquartile range) of 3.9 (2.0-4.0) years. Recruitment of participants started in May 2008 and ended in February 2011. Follow-up ended in April 2016. Data analysis was conducted from April to October 2020.

Exposure: Plasma Aβ42 and Aβ40 were measured at 12 months for 448 participants (92.8%) and at 24 months for the rest. The moment of Aβ assessment was defined as the baseline for this study.

Main outcomes and measures: Cognitive function was assessed at 12, 24, 36, 48, and 60 months by a composite cognitive score based on 4 tests; Mini Mental State Examination (MMSE); Clinical Dementia Rating, sum of boxes; and Alzheimer Disease Cooperative Study-Activities of Daily Living. Mixed-effect linear regressions were performed.

Results: A total of 483 participants (median [IQR] age, 76.0 [73.0-80.0]; 286 [59.2%] women) were analyzed. Of them, 161 (33.3%) were classified as low plasma Aβ42/40 (≤0.107). After adjusting for age, sex, education, body mass index, Geriatric Depression Scale score, apolipoprotein E ε4 genotype, and MAPT intervention groups, low plasma Aβ42/40 was associated with more pronounced decline in composite cognitive score (adjusted between-group mean difference: -0.20, 95% CI, -0.34 to -0.07; P = .004) and decline in MMSE score (adjusted between-group mean difference: -0.59; 95% CI, -1.07 to -0.11; P = .02) during the follow-up period compared with the group with an Aβ42/40 ratio greater than 0.107.

Conclusions and relevance: In this study, low plasma Aβ42/40 was associated with more pronounced decline in cognitive function (measured by multiple outcomes) over time. Findings suggest that plasma Aβ42/40 may be used to identify people at risk of cognitive decline, being an alternative to more complex and expensive measures, such as positron emission tomography imaging or cerebrospinal fluid measurement.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Bateman reported receiving personal fees from C2N Diagnostics, Amgen, AC Immune, Eisai, Hoffman-LaRoche, and Janssen Pharmaceuticals outside the submitted work; having equity ownership in C2N Diagnostics; receiving income based on a blood plasma assay licensed by Washington University to C2N Diagnostics; receiving income from C2N Diagnostics for serving on the scientific advisory board; and having a patent (“Plasma Based Methods for Determining A-Beta Amyloidosis”) pending with Washington University. Dr Vellas reported receiving grants and personal fees from Biogen, Roche, and Merck outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Flow Diagram Describing the Population of the Study
Aβ indicates amyloid-β.
Figure 2.
Figure 2.. Variation in Outcomes Over Time According to Plasma Amyloid-β42/40 Status Among Community-Dwelling Older Adults
ADCS-ADL indicates Alzheimer Disease Cooperative Study–Activities of Daily Living. aP < .05 for adjusted between-group difference according to the cutoff of 0.107. bP < .05 for adjusted between-group difference according to the cutoff of 0.103. cP < .05 for adjusted between-group difference according to the cutoffs of 0.107 and 0.103.
See this image and copyright information in PMC

References

    1. Jack CR Jr, Bennett DA, Blennow K, et al. ; Contributors . NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018 - DOI - PMC - PubMed
    1. Ovod V, Ramsey KN, Mawuenyega KG, et al. . Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841-849. doi:10.1016/j.jalz.2017.06.2266 - DOI - PMC - PubMed
    1. Nakamura A, Kaneko N, Villemagne VL, et al. . High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018;554(7691):249-254. doi:10.1038/nature25456 - DOI - PubMed
    1. Wang X, Sun Y, Li T, Cai Y, Han Y. Amyloid-β as a blood biomarker for Alzheimer’s disease: a review of recent literature. J Alzheimers Dis. 2020;73(3):819-832. doi:10.3233/JAD-190714 - DOI - PubMed
    1. Bateman RJ, Blennow K, Doody R, et al. . Plasma biomarkers of AD emerging as essential tools for drug development: an EU/US CTAD Task Force report. J Prev Alzheimers Dis. 2019;6(3):169-173. - PubMed

Publication types